-+ 0.00%
-+ 0.00%
-+ 0.00%

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation

Barchart·01/05/2026 05:30:00
Listen to the news

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect 

NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.